The opposition period prior to finalization of a patent allowance application submitted by MicroBiome Therapeutics LLC regarding the use of its glyceollin therapy for the treatment of both obesity and diabetes has expired. The clinical stage biotechnology company announced in a press release that it has received a notice of allowance from the U.S. Patent and Trademark Office accepting the therapy.
MicroBiome Therapeutics is studying the use of glyceollin I, II and III, which are small molecule natural products based on soy plants, for the treatment of metabolic conditions, and expect it to be able to modulate the gastrointestinal microbiome, becoming an effective treatment for obesity and diabetes. In addition, the natural product may have capacities to combat infectious organisms and other stress factors.
The company’s scientists have conducted animal studies on numerous human disease models, in which glyceollin’s capacities were revealed, showing encouraging results regarding breast and ovarian cancer, hyper-cholesterolemia and metabolic disorders. “MBT researchers have been studying glyceollins for some time, and we are excited about their potential as novel agents for the treatment of diabetes and obesity,” stated the CEO of MicroBiome Therapeutics, Steve Orndorff, PhD.
“We are encouraged too by the results of our recently completed animal studies assessing whether glyceollin can affect the regulation of blood glucose, and we look forward to reporting the findings in a peer-reviewed forum,” added Orndorff. “We also plan to study glyceollins as part of our gastrointestinal microbiome modulator (GIMM) program, whose lead products, NM 504 and NM 505, have demonstrated positive results in pilot clinical studies in diabetes and prediabetes.”
The next step will be to apply for a patent for the product, and the company has further announced its plans to file U.S. Patent Application No.: 12/976,209, with the title: Compositions and Methods for Treating Obesity and Diabetes within the following months. “With the broad claims of this new patent now assured, we intend to move ahead with this promising new approach to these conditions that adversely impact millions of people worldwide,” said the CEO.
The company also recently presented the latest data on the development of glyceollin at the One-on-One Partnering sessions of the 17th Annual BIO CEO and Investor Conference, a major event that gathered investors and biotech companies between February 9 and 10 at The Waldorf Astoria in New York City.
